H.C. Wainwright lowered the firm’s price target on Aeon Biopharma to $6 from $18 and keeps a Buy rating on the shares. After two setbacks with ABP-450’s migraine program, Aeon must now navigate its path forward with limited capital, the analyst tells investors in a research note. The firm says additional funding is needed to advance its programs. It remains confident in the potential of ABP-450 and awaits the company’s updated business plans for clarity on the next steps.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AEON:
- Aeon Biopharma provides update on development pipeline
- Aeon’s results from Phase 2 trial of ABP-450 didn’t meet primary endpoint
- AEON Biopharma Phase 2 Migraine Treatment Trial Results
- AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
- AEON Biopharma Bolsters Finance and Board with Daewoong Deal